SCBT-MR 2015 LungRADS : Basics
|
|
- Stanley Cameron
- 5 years ago
- Views:
Transcription
1 SCBT-MR 2015 LungRADS : Basics Reginald F. Munden MD, DMD, MBA I have no conflicts of interest to report
2 National Lung Cancer Screening Trial 20% lung cancer mortality reduction 6.9% all cause mortality reduction 320 individuals to save 1 from lung cancer death
3 NLST 24% of all screens - called positive study T0-27%, T1-28%, T2-17% 96% of positive studies - false positive At least one positive study in participant: CT 39%; CXR 16% Complications: 0.4% CT; 1.6% CXR 16 deaths (within 60 days) of CT (10 lung cancer) False negative - missed rate? NLST Research Team. NEJM, 2011
4 Lung Cancer Screening: Standardized lung nodule identification ACR LungRADS
5 ACR LungRADS Category Descriptor Category Descriptor Primary Category Incomplete - 0 Negative No nodules & definitely benign nodules 1 Management Additional lung cancer screening CT images and/or comparison to prior chest CT examinations is needed Benign Appearance or Behavior Nodules with a very low likelihood of becoming a clinically active cancer due to size or lack of growth 2 Continue annual screening with LDCT in 12 months Probably Benign Probably benign finding(s) - short term follow up suggested; includes nodules with a low likelihood of becoming a clinically active cancer 3 6 month LDCT 4A 3 month LDCT; PET/CT may be used when there is a 8 mm solid component Suspicious Findings for which additional diagnostic testing and/or tissue sampling is recommended 4B Chest CT, PET/CT and/or biopsy-depending on *probability of malignancy and comorbidities.
6 ACR LUNG-RADS Category Category Descriptor Category Findings Management Probability of Malignancy Estimated Population Prevalence Negative No nodules and definitely benign nodules 1 no lung nodules nodule(s) with specific calcifications: complete, central, popcorn, concentric rings and fat containing nodules Benign Appearance or Behavior Nodules with a very low likelihood of becoming a clinically active cancer due to size or lack of growth 2 solid nodule(s): < 6 mm new < 4 mm part solid nodule(s): < 6 mm total diameter on baseline screening non solid nodule(s) (GGN): < 20 mm OR 20 mm and unchanged or slowly growing Continue annual screening with LDCT in 12 months < 1% 90% category 3 or 4 nodules unchanged for 3 months Probably Benign Probably benign finding(s) - short term follow up suggested; includes nodules with a low likelihood of becoming a clinically active cancer 3 solid nodule(s): 6 to < 8 mm at baseline OR new 4 mm to < 6 mm part solid nodule(s): 6 mm total diameter with solid component < 6 mm OR new < 6 mm total diameter non solid nodule(s) (GGN) 20 mm on baseline CT or new 6 month LDCT 1-2% 5%
7 ACR LungRADS Category 4 Category Category Descriptor Category Findings Management Probability of Malignancy Estimated Population Prevalence Solid nodule(s): 8 to < 15 mm at baseline OR growing < 8 mm OR new 6 to < 8 mm 3 month LDCT; 4A Part solid nodule(s): 6 mm with solid component 6 mm to < 8 mm OR PET/CT may be used when there is a 8 mm solid component 5-15% 2% Suspicious Findings for which additional diagnostic testing and/or tissue sampling is recommended 4B 4X with a new or growing < 4 mm solid component Endobronchial nodule Solid nodule(s) 15 mm OR new or growing, and 8 mm Part solid nodule(s) with: a solid component 8 mm OR a new or growing 4 mm solid component Category 3 or 4 nodules with additional features or imaging findings that increases the suspicion of malignancy Chest CT with or without contrast; PET/CT and/or tissue sampling depending on the *probability of malignancy and comorbidities; PET/CT may be used when there is a 8 mm solid component. > 15% 2%
8 Baseline 3 months follow-up 4A Management
9 4A - Solid Nodule Findings > 8 to < 15mm at baseline Growing < 8mm or New 6 to < 8mm Endobronchial nodule Management: 3 month LDCT PET/CT if solid component is > 8mm
10 Follow up 3 months PET/CT 4A Solid > 8mm to < 15mm at baselline
11 4A: Growing < 8m One year
12 4A Endobronchial
13 Category 4A Part-solid Nodule Category Category Descriptor Category Findings Management Probability of Malignancy Estimated Population Prevalence Suspicious Findings for which additional diagnostic testing and/or tissue sampling is recommended 4A Part solid nodule(s): 6 mm with solid component 6mm to < 8 mm OR with a new or growing < 4 mm solid component 3 month LDCT; PET/CT may be used when there is a 8 mm solid component 5-15% 2%
14 Findings: > 6 mm with solid component > 6mm to < 8mm or with a new or growing < 4mm solid component Management: 3 month LDCT PET/CT if solid component is > 8mm 4A Part Solid Nodule
15 New < 4mm Solid Component 4A Part Solid Nodule
16 Category 4B Solid Nodule Category Category Descriptor Category Findings Management Suspicious Findings for which additional diagnostic testing and/or tissue sampling is recommended 4B Solid nodule(s) 15 mm OR new or growing, and 8 mm Chest CT with or without contrast; PET/CT and/or tissue sampling depending on the *probability of malignancy and comorbidities; PET/CT may be used when there is a 8 mm solid component. Probability of Malignancy Estimated Population Prevalence > 15% 2%
17 4B Solid Nodule Findings > 15mm at baseline or New or growing, and > 8mm Management Chest CT w/ or w/o contrast PET/CT and/or tissue sampling depending on probability of malignancy
18 4B - Growing and > 8mm
19 Category 4B Part-Solid Nodule Category Category Descriptor Category Findings Management Probability of Malignancy Estimated Population Prevalence Suspicious Findings for which additional diagnostic testing and/or tissue sampling is recommended 4B Part solid nodule(s) with: a solid component 8 mm OR a new or growing 4 mm solid component Chest CT with or without contrast; PET/CT and/or tissue sampling depending on the *probability of malignancy and comorbidities; PET/CT may be used when there is a 8 mm solid component. > 15% 2%
20 4B New > 8mm solid
21 4B Growing Solid Component
22 4x Category Category Descriptor Category Findings Management Probability of Malignancy Estimated Population Prevalence Chest CT with or without contrast; Suspicious Findings for which additional diagnostic testing and/or tissue sampling is recommended 4X Category 3 or 4 nodules with additional features or imaging findings that increases the suspicion of malignancy PET/CT and/or tissue sampling depending on the *probability of malignancy and comorbidities; PET/CT may be used when there is a 8 mm solid component. > 15% 2% Increases the suspicion of malignancy: Spiculations, edge contours Hilar/central mass small cell cancer GGN doubles in size in 1 year Calcification
23 Findings Additional imaging features that increase the suspicion of malignancy: Spiculations, hilar/central mass, GGN doubles in size in 1 year Management Chest CT w/w/o contrast PET/CT and/or tissue sampling depending on probability of malignancy 4x - Other Stuff
24 4x Other suspicious
25 4B Management Factors Patient preference Probability of malignancy based on patient evaluation McWilliams Lung Cancer Risk Calculator
26 McWilliams Lung Cancer Risk Calculator
27 Category S and C Category Category Descriptor Category Findings Management Probability of Malignancy Estimated Population Prevalence Other Clinically Significant or Potentially Significant Findings (non-lung cancer) S Modifier - may add on to category 0 4 coding As appropriate to the specific findings n/a 10% Prior Lung Cancer Modifier for patients with a prior diagnosis of lung cancer who return to screening C Modifier may add on to category 0 4 coding
28 Coronary Artery Calcification as a Predictor of Morality in the NLST 1575 NLST CTs graded for CAC 210 CHD deaths, 315 all cause deaths, 1050 alive Agatston score, qualitative vessel, overall visual CAC classification HR overall assessment HR vessel-specific segments HR Agatston score None/0/ Mild/1-5/ Moderate/6-11/101-1, Heavy/12-30/>1, Chiles, et al. Radiology2014
29 Thank You Reginald F. Munden MD, DMD, MBA
SCBT-MR 2016 Lung Cancer Screening in Practice: State of the Art
SCBT-MR 2016 Lung Cancer Screening in Practice: State of the Art Reginald F. Munden MD, DMD, MBA I have no conflicts of interest to report National Lung Cancer Screening Trial 20% lung cancer mortality
More informationSCBT-MR 2015 Incidentaloma on Chest CT
SCBT-MR 2015 Incidentaloma on Chest CT Reginald F. Munden MD, DMD, MBA I have no conflicts of interest to report Incidentaloma Pulmonary Nodule Mediastinal Lymph Node Coronary Artery Calcium Incidental
More informationLearning Objectives. 1. Identify which patients meet criteria for annual lung cancer screening
Disclosure I, Taylor Rowlett, DO NOT have a financial interest /arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context
More informationCurrent Approach to Screening for Lung Cancer. James R Jett M.D.
Current Approach to Screening for Lung Cancer James R Jett M.D. Potential Conflicts of Interest I am Chief Medical Officer for Oncimmune Ltd (Biomarkers of Cancer) Co-Editor of Lung Cancer Section of UP-TO-DATE
More informationScreening Programs background and clinical implementation. Denise R. Aberle, MD Professor of Radiology and Engineering
Screening Programs background and clinical implementation Denise R. Aberle, MD Professor of Radiology and Engineering disclosures I have no disclosures. I have no conflicts of interest relevant to this
More informationThe Maine Lung Cancer Coalition. Working Together to Reduce Lung Cancer in Maine
The Maine Lung Cancer Coalition Working Together to Reduce Lung Cancer in Maine funding Maine Lung Cancer Coalition (MLCC) Webinar Lung Cancer Screening: Following Up On Abnormal Low Dose CT Scans with
More informationPULMONARY NODULES DETECTED INCIDENTALLY OR BY SCREENING: LOTS OF GUIDELINES BUT WHERE IS THE EVIDENCE?
PULMONARY NODULES DETECTED INCIDENTALLY OR BY SCREENING: LOTS OF GUIDELINES BUT WHERE IS THE EVIDENCE? MICHAEL K. GOULD, MD SENIOR RESEARCH SCIENTIST DIRECTOR FOR HEALTH SCIENCES & IMPLEMENTATION SCIENCE
More informationCLINICAL GUIDELINES. Lung-Cancer Screening Program Guidelines Robert Y. Kanterman, M.D. and Thomas J. Gilbert, M.D., M.P.P.
CLINICAL GUIDELINES Lung-Cancer Screening Program Guidelines Robert Y. Kanterman, M.D. and Thomas J. Gilbert, M.D., M.P.P. 3/14/2015 Introduction: The purpose of a lung-cancer screening program is to detect
More informationSHARED DECISION MAKING AND LUNG CANCER SCREENING
SHARED DECISION MAKING AND LUNG CANCER SCREENING DISCLOSURES Cathleen E. Morrow, MD None William C. Black, MD No financial disclosure Co-investigator for NLST Member of the ACR Lung-RADS Screening Registry
More informationPULMONARY NODULES AND MASSES : DIAGNOSTIC APPROACH AND NEW MANAGEMENT GUIDELINES. https://tinyurl.com/hmpn2018
PULMONARY NODULES AND MASSES : DIAGNOSTIC APPROACH AND NEW MANAGEMENT GUIDELINES Heber MacMahon MB, BCh Department of Radiology The University of Chicago https://tinyurl.com/hmpn2018 Disclosures Consultant
More informationApproach to Pulmonary Nodules
Approach to Pulmonary Nodules Edwin Jackson, Jr., DO Assistant Professor-Clinical Director, James Early Detection Clinic Department of Internal Medicine Division of Pulmonary, Allergy, Critical Care and
More informationGUIDELINES FOR PULMONARY NODULE MANAGEMENT : RECENT CHANGES AND UPDATES
Venice 2017 GUIDELINES FOR PULMONARY NODULE MANAGEMENT : RECENT CHANGES AND UPDATES Heber MacMahon MB, BCh Department of Radiology The University of Chicago Disclosures Consultant for Riverain Medical
More informationLung Cancer Screening
Lung Cancer Screening Steven Leh, MD, FCCP Diplomat of the American Association for Bronchology and Interventional Pulmonology Aurora Medical Group Pulmonary and Sleep Medicine February 10, 2018 Disclosures
More informationPublished Pulmonary Nodule Guidelines A Synthesis
Published Pulmonary Nodule Guidelines A Synthesis Dr A Devaraj Royal Brompton Hospital London 4/28/2015 1 And very soon to be published Published ^ Pulmonary Nodule Guidelines A Synthesis Dr A Devaraj
More informationCT Screening for Lung Cancer for High Risk Patients
CT Screening for Lung Cancer for High Risk Patients The recently published National Lung Cancer Screening Trial (NLST) showed that low-dose CT screening for lung cancer reduces mortality in high-risk patients
More informationLung Cancer Screening: To Screen or Not to Screen?
Lung Cancer Screening: To Screen or Not to Screen? Lorriana Leard, MD Co-Director of UCSF Lung Cancer Screening Program Vice Chief of Clinical Activities UCSF Pulmonary, Critical Care, Allergy & Sleep
More informationPulmonary Nodules & Masses
Pulmonary Nodules & Masses A Diagnostic Approach Heber MacMahon The University of Chicago Department of Radiology Disclosure Information Consultant for Riverain Technology Minor equity in Hologic Royalties
More informationPulmonary Nodules. Michael Morris, MD
Pulmonary Nodules Michael Morris, MD Case 45 year old healthy male Smokes socially Normal physical exam Pre-employment screening remote +PPD screening CXR nodular opacity Case 45 year old healthy male
More informationLung Cancer Screening:
Lung Cancer Screening: Maximizing Gain and Dealing with Pandora s Box Mark M. Fuster, MD Division of Pulmonary & Critical Care UCSD Department of Medicine & VA San Diego Healthcare Service San Diego, CA
More informationLung Cancer Risk Associated With New Solid Nodules in the National Lung Screening Trial
Cardiopulmonary Imaging Original Research Pinsky et al. Lung Cancer Risk Associated With New Nodules Cardiopulmonary Imaging Original Research Paul F. Pinsky 1 David S. Gierada 2 P. Hrudaya Nath 3 Reginald
More informationLung Cancer Screening
Scan for mobile link. Lung Cancer Screening What is lung cancer screening? Screening examinations are tests performed to find disease before symptoms begin. The goal of screening is to detect disease at
More informationThe status of Lung Cancer Screening Guidelines. Peter B. Bach, MD, MAPP Memorial Sloan Kettering Cancer Center
The status of Lung Cancer Screening Guidelines Peter B. Bach, MD, MAPP Memorial Sloan Kettering Cancer Center bachp@mskcc.org @peterbachmd Homogeneity of guidelines But what about these? Outside the box
More informationLung Cancer Screening: To screen or not to screen?
Lung Cancer Screening: To screen or not to screen? Dan J. Raz, M.D. Co Director, Lung Cancer Screening Program Co Director, LungCancer and Thoracic OncologyProgram Assistant Professor, Thoracic Surgery
More informationLung Cancer Screening
Scan for mobile link. Lung Cancer Screening What is lung cancer screening? Screening examinations are tests performed to find disease before symptoms begin. The goal of screening is to detect disease at
More informationExample of lung screening
Justification of the use of CT for individual health assessment of asymptomatic people How to obtain evidence for IHA - Example of lung screening Mathias Prokop, MD PhD Professor of Radiology Radboud University
More informationCT Lung Screening Implementation Challenges: State Based Initiatives
CT Lung Screening Implementation Challenges: State Based Initiatives Andrea McKee, MD Chair Radiation Oncology Lahey Hospital and Medical Center Co-Director Rescue Lung, Rescue Life Program Co-Chair Massachusetts
More informationLung Cancer Screening: Who, What, Why? Myths Dispelled
Lung Cancer Screening: Who, What, Why? Myths Dispelled Presented By: MaryAnn Tateosian, RT (R), M, MM, CIIP MGH Lung Screening Program Manager December 11, 2018 1 Lung Screening Objectives History of Smoking
More informationLUNG NODULES: MODERN MANAGEMENT STRATEGIES
Department of Radiology LUNG NODULES: MODERN MANAGEMENT STRATEGIES Christian J. Herold M.D. Department of Biomedical Imaging and Image-guided Therapy Medical University of Vienna Vienna, Austria Pulmonary
More informationPulmonary Nodules: When to worry, when to chill. Douglas Arenberg Associate Professor Pulmonary & Critical Care
Pulmonary Nodules: When to worry, when to chill Douglas Arenberg Associate Professor Pulmonary & Critical Care Disclosure MDCH Grant Funds to improve tobacco cessation service in the Michigan Medicine
More informationI9 COMPLETION INSTRUCTIONS
The I9 Form is completed for each screening exam at T0, T1, and T2. At T0 (baseline), the I9 documents comparison review of the baseline screen (C2 Form) with any historical images available. At T1 and
More informationObjectives. Why? Why? Background 11/5/ % incurable disease at presentation Locally advanced disease Metastasis. 14% 5 year survival
Objectives Appraise lung cancer screening trials results Review screening guidelines Lung Cancer Screening: Past, Present and Future Chi Wan Koo, MD Koo.chiwan@mayo.edu Discuss recommendations essential
More informationRole of CT in Lung Cancer Screening: 2010 Stuart S. Sagel, M.D.
Role of CT in Lung Cancer Screening: 2010 Stuart S. Sagel, M.D. Lung Cancer 219,440 new cases/year in U.S. (2009) 169,390 deaths/year in U.S. mortality greater than from breast, colon, prostate CA combined
More informationRodney C Richie MD FACP FCCP DBIM Texas Life and EMSI
Rodney C Richie MD FACP FCCP DBIM Texas Life and EMSI Pulmonary Nodules Well-circumscribed, radiographic opacities measuring 3 cm in diameter Surrounded by aerated lung Not associated with atelectesis
More informationNone
2014 None rosemary clooney Cancer is one of the most common diseases in the developed world: 1 in 4 deaths are due to cancer 1 in 17 deaths are due to lung cancer Lung cancer is the most common
More informationEvidence based approach to incidentally detected subsolid pulmonary nodule. DM SEMINAR July 27, 2018 Harshith Rao
Evidence based approach to incidentally detected subsolid pulmonary nodule DM SEMINAR July 27, 2018 Harshith Rao Outline Definitions Etiologies Risk evaluation Clinical features Radiology Approach Modifications:
More informationLung Cancer Screening Trials. Edward Harris Respiratory Research Fellow Sir Charles Gairdner Hospital
Lung Cancer Screening Trials Edward Harris Respiratory Research Fellow Sir Charles Gairdner Hospital Lung Cancer Screening in Australia Not Funded except as part of a clinical trial Rationale PLCO, ELCAP
More informationChest Radiology Interpretation: Findings of Tuberculosis
Chest Radiology Interpretation: Findings of Tuberculosis Get out your laptops, smart phones or other devices pollev.com/chestradiology Case #1 1 Plombage Pneumonia Cancer 2 Reading the TB CXR Be systematic!
More informationUW Radiology Review Course Breast Calcifications. BI-RADS 5 th Edition
UW Radiology Review Course Breast Calcifications Grace Kalish, MD Vantage Radiology BI-RADS 5 th Edition Benign Skin Vascular Large rod like Coarse popcorn Suspicious Amorphous Coarse heterogenous Fine
More informationLUNG CANCER SCREENING: LUNG CANCER SCREENING: THE TIME HAS COME LUNG CANCER: A NATIONAL EPIDEMIC
: THE TIME HAS COME Physician Leader, Lung Cancer Multi-Disciplinary Program Fletcher Allen Health Care Annual Meeting Montpelier, VT - April 25, 2014 Gerald S. Davis, MD Professor of Medicine University
More informationPulmonologist s Perspective
Low-dose CT for lung cancer screening Pulmonologist s Perspective Literature Review Kang-Yun Lee, MD PhD Department of Thoracic Medicine Taipei Medical University- Shuang Ho Hospital Taiwan Local vs. Advanced
More informationDisclosures CORONARY CALCIUM SCORING REVISITED. Learning Objectives. Scoring Methods. Consultant for M2S, Inc. Coronary Calcium Scoring: Software
CORONARY CALCIUM SCORING REVISITED Disclosures Consultant for M2S, Inc. Julianna M. Czum, MD Director, Division of Cardiothoracic Imaging Department of Radiology Dartmouth Hitchcock Medical Center Assistant
More informationImaging in breast cancer. Mammography and Ultrasound Donya Farrokh.MD Radiologist Mashhad University of Medical Since
Imaging in breast cancer Mammography and Ultrasound Donya Farrokh.MD Radiologist Mashhad University of Medical Since A mammogram report is a key component of the breast cancer diagnostic process. A mammogram
More informationScreening for Lung Cancer: New Guidelines, Old Problems
Screening for Lung Cancer: New Guidelines, Old Problems Robert Schilz DO, PhD Associate Professor of Medicine Interim Chief of the Division of Pulmonary, Critical Care and Sleep Medicine University Hospitals
More informationUltralow Dose Chest CT with MBIR
Ultralow Dose Chest CT with MBIR Ella A. Kazerooni, M.D. Professor & Director Cardiothoracic Radiology Associate Chair for Clinical Affairs University of Michigan Disclosures Consultant: GE Healthcare
More informationChristine Argento, MD Interventional Pulmonology Emory University
Christine Argento, MD Interventional Pulmonology Emory University Outline Lung Cancer Statistics Prior Studies for Lung Cancer Screening NLST Studies Following NLST Future Directions Lung Cancer American
More informationLung Cancer Screening: Evidence and current recommendations
Lung Cancer Screening: Evidence and current recommendations 20 th March 2018 Dr Annette McWilliams Fiona Stanley Hospital University of Western Australia WA Cancer & Palliative Care Network I have no financial
More informationA Comprehensive Cancer Center Designated by the National Cancer Institute
N C I C C C A Comprehensive Cancer Center Designated by the National Cancer Institute Screening and Early Detection of Lung Cancer: Ready for Practice? David S. Ettinger, MD, FACP, FCCP Alex Grass Professor
More information10/17/16. Lung Cancer Screening. Question 1: Does lung cancer screening make sense? 3rd lung cancer third most prevalent tumor type
Lung Cancer Screening Greg Rogalski Mercy Radiology Group greg@grogo.org Question 1: Does lung cancer screening make sense? 2 Requirements for successful screening process Sufficiently high prevalence
More informationLung Screening: Do s and Don t s
18th Annual Interna3onal Symposium on Mul3detector-Row CT June 20-23 2015 HyaH Regency San Franciscio Wednesday June 22 7.00 AM Lung Screening: Do s and Don t s Mathias Prokop, MD PhD Department of Radiology
More informationObserver variability for Lung-RADS categorisation of lung cancer screening CTs: impact on patient management
European Radiology https://doi.org/10.1007/s00330-018-5599-4 CHEST Observer variability for Lung-RADS categorisation of lung cancer screening CTs: impact on patient management Sarah J. van Riel 1 & Colin
More informationVA PARTNERSHIP Increase ACCESS to LUNG SCREENING
VA PARTNERSHIP Increase ACCESS to LUNG SCREENING Project PI: Drew Moghanaki, MD, MPH Clinical Co-PI: Claudia Henschke, PhD, MD Technical Co-PI: Rick Avila, MS Sponsored by the Bristol-Myers Squibb Foundation
More informationImplementation & optimization of a lung cancer screening CT program. Presented by Izabella Barreto at the 2016 Florida AAPM Chapter Meeting
Implementation & optimization of a lung cancer screening CT program Presented by Izabella Barreto at the 2016 Florida AAPM Chapter Meeting Izabella Barreto, Nathan Quails, Catherine Carranza, Nathalie
More informationLung Cancer screening :
Lung Cancer screening : Pro-Contra SAMO interdisciplinary workshop on chest tumors 27 and 28 january 2017 Prof L.P.Nicod Sevice de pneumologie CHUV-Lausanne -CH Lung Cancer How big is the problem? Epidemiology
More informationLung Cancer Screening: Benefits and limitations to its Implementation
Lung Cancer Screening: Benefits and limitations to its Implementation Rolando Sanchez, MD Clinical Assistant Professor Pulmonary-Critical Care Medicine University of Iowa Lung cancer - Epidemiology Cancer
More informationVeterans Health Administration Lung Cancer Screening Demonstration Project: Results & Lessons Learned
Veterans Health Administration Lung Cancer Screening Demonstration Project: Results & Lessons Learned Jane Kim, MD, MPH Acting Chief Consultant for Preventive Medicine National Center for Health Promotion
More informationI8 COMPLETION INSTRUCTIONS
The I8 Form is completed for each screening exam at T0, T1, and T2. At T0 (baseline), the I8 Form documents comparison review of the baseline screen (DR Form) with any historical images available. At T1
More informationAnn Intern Med. 2012;156(5):
Lung Cancer Screening Update Doug Arenberg, M.D. University of Michigan Outline Screening; Some simple but necessary truths Do people benefit from screening? What are the harms (and are they outweighed
More informationThe Spectrum of Management of Pulmonary Ground Glass Nodules
The Spectrum of Management of Pulmonary Ground Glass Nodules Stanley S Siegelman CT Society 10/26/2011 No financial disclosures. Noguchi M et al. Cancer 75: 2844-2852, 1995. 236 surgically resected peripheral
More informationDisclosures. Overview. Selection the most accurate statement: Updates in Lung Cancer Screening 5/26/17. No Financial Disclosures
Updates in Lung Cancer Screening Disclosures No Financial Disclosures Neil Trivedi, MD Associate Professor of Clinical Medicine SF VAMC Pulmonary and Critical Care Director, Bronchoscopy & Interventional
More informationLung Cancer Diagnosis for Primary Care
Lung Cancer Diagnosis for Primary Care Daniel Nader, DO, FCCP Cancer Treatment Center of America Case 1 In which of the following situations would the U.S. Preventive Services Task Force (USPSTF) recommend
More informationNew Paradigms in Predicting CVD Risk
New Paradigms in Predicting CVD Risk Imaging as an Integrator of Lifetime Risk Exposure Michael J. Blaha MD MPH Presented by: Michael J. Blaha September 24, 2014 1 Talk Outline Risk factors vs. Disease
More informationLung Cancer Screening Computed Tomography Screening in Pa6ents at Risk for Lung Cancer
Lung Cancer Screening Computed Tomography Screening in Pa6ents at Risk for Lung Cancer Doug Arenberg, M.D. University of Michigan Disclosures Objec6ve Define patients who will benefit from screening for
More informationCase-based discussion:
Case-based discussion: Pailin Kongmebhol, M.D. Department of Radiology Faculty of Medicine Chiang Mai University There are many guidelines for managing thyroid nodules Two important guidelines: 2015 American
More informationMANAGEMENT RECOMMENDATIONS
1 MANAGEMENT RECOMMENDATIONS 1. Adrenal masses!!!!!!! page 2 2. Liver Masses!!!!!!! page 3 3. Obstetric US Soft Markers for Aneuploidy!! pages 4-6 4. Ovarian and Adnexal Cysts!!!!! pages 7-10 5. Pancreatic
More informationDISCLOSURE. Lung Cancer Screening: The End of the Beginning. Learning Objectives. Relevant Financial Relationship(s) Off Label Usage
Peninsula Regional Medical Center 12 th Annual Lung Cancer Conference March 9, 2017 Lung Cancer Screening: The End of the Beginning David E. Midthun M.D. Professor of Medicine College of Medicine, Mayo
More informationWhat to know and what to make of it
Lung Cancer Screening: What to know and what to make of it J. Matthew Reinersman, MD Assistant Professor of Surgery Division of Thoracic and Cardiovascular Surgery Department of Surgery University of Oklahoma
More informationBI-RADS Update. Martha B. Mainiero, MD, FACR, FSBI Brown University Rhode Island Hospital
BI-RADS Update Martha B. Mainiero, MD, FACR, FSBI Brown University Rhode Island Hospital No Disclosures BI-RADS History 1980s Quality Issues ACR Accreditation BI-RADS 1994 2003 4 th Edition MRI, US January
More informationAbstract Submission Form
Abstract Submission Form All abstracts must be submitted to the AOCR by September 15 th. All information included must be the original work of the author(s) and be in typed form. Incomplete or handwritten
More informationDOH LUNG CANCER SCREENING SERVICE SPECIFICATIONS
DOH LUNG CANCER SCREENING SERVICE SPECIFICATIONS December 2018 Page 1 of 18 Document Title: Document Ref. Number: DOH Lung Cancer Screening Service Specifications PH/NCD/LCSC/SR/0.9 Version: 0.9 Approval
More informationDeep Learning, Lung Cancer Screening & the Data Science Bowl 2017
Deep Learning, Lung Cancer Screening & the Data Science Bowl 2017 Bram van Ginneken, Arnaud Arindra Adiyoso Setio, Colin Jacobs Diagnostic Image Analysis Group, Radboud University Medical Center, Nijmegen,
More informationLUNG CANCER SCREENING: ON WHOM DID YOU DO IT AND ON WHOM DO YOU RESPOND TO THE RESULTS?
LUNG CANCER SCREENING: ON WHOM DID YOU DO IT AND ON WHOM DO YOU RESPOND TO THE RESULTS? DAVID O. WILSON, MD, MHP DIRECTOR GEORGIA COOPER MEMORIAL LUNG CANCER RESEARCH REGISTRY UNIVERSITY OF PITTSBURGH
More informationAmammography report is a key component of the breast
Review Article Writing a Mammography Report Amammography report is a key component of the breast cancer diagnostic process. Although mammographic findings were not clearly differentiated between benign
More informationAmerican College of Radiology ACR Appropriateness Criteria
American College of Radiology ACR Criteria Radiologic Management of Thoracic Nodules and Masses Variant 1: Middle-aged patient (35 60 years old) with an incidental 1.5-cm lung nodule. The lesion was smooth.
More informationAn Update on Lung Cancer Screening Policy and the Role of Quitlines
An Update on Lung Cancer Screening Policy and the Role of Quitlines Robert J. Volk, PhD Vance Rabius, PhD The University of Texas MD Anderson Cancer Center North American Quitline Consortium NAQC Conference
More informationLung Cancer Screening in the Midwest of the US: When Histoplasmosis Complicates the Picture
Cronicon OPEN ACCESS EC PULMONOLOGY AND RESPIRATORY MEDICINE Case Report Lung Cancer Screening in the Midwest of the US: When Histoplasmosis Complicates the Picture Swan Lee 1 and Rolando Sanchez Sanchez
More informationLung Cancer Screening: A review of the recommendations Friday, November 11th, 2016 from 11:45 to 12:15. Dr. Tunji Fatoye Dr.
Lung Cancer Screening: A review of the recommendations Friday, November 11th, 2016 from 11:45 to 12:15 Dr. Tunji Fatoye Dr. Alan Kaplan Conflict of Interest Disclosure: Speaker Name: Alan Kaplan FINANCIAL
More informationLeonard M. Glassman MD
BI-RADS The New BI-RADS Leonard M. Glassman MD FACR Former Chief of Breast Imaging American Institute for Radiologic Pathology Washington Radiology Associates, PC Breast Imaging Reporting and Data System
More informationInternational Early Lung Cancer Action Program: Screening Protocol PI: Claudia I. Henschke, PhD, MD New York, New York
International Early Lung Cancer Action Program: Screening Protocol PI: Claudia I. Henschke, PhD, MD New York, New York Overview... 2 Indications for screening... 2 Frequency of screening... 2 Communication
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #364: Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines National Quality
More informationLung cancer Screening
Lung cancer Screening Family Physicians and CancerControl 2018 Alain Tremblay Division of Respiratory Medicine University of Calgary Disclosures BD Inc - Consultant / Medical Device development Olympus
More informationVHA Demonstration Project for Lung Cancer Screening Using Low-Dose Chest CT Screening
VHA Demonstration Project for Lung Cancer Screening Using Low-Dose Chest CT Screening ATS San Francisco 2016 James K. Brown MD 1, Kathryn L. Rice, MD 2 (1) San Francisco VA (2) Minneapolis VAMC Disclosures
More informationRobert J. McKenna M.D. Chief, Thoracic Surgery Cedars Sinai Medical Center
You Smoke, You Get Lung Cancer, You Die: Can Screening Change this Paradigm? Robert J. McKenna M.D. Chief, Thoracic Surgery Cedars Sinai Medical Center AATS Saturday 4/28/2012 Cancer Screening Cancer
More informationLUNG CANCER SCREENING WHAT S THE IMPACT? Nitra Piyavisetpat, MD Department of Radiology Chulalongkorn University
LUNG CANCER SCREENING WHAT S THE IMPACT? Nitra Piyavisetpat, MD Department of Radiology Chulalongkorn University Objective LDCT lung cancer screening (LCS) Potential Benefits & Harms Recommendation of
More informationLUNG CANCER continues to rank as the leading cause
1138 IEEE TRANSACTIONS ON MEDICAL IMAGING, VOL. 24, NO. 9, SEPTEMBER 2005 Computer-Aided Diagnostic Scheme for Distinction Between Benign and Malignant Nodules in Thoracic Low-Dose CT by Use of Massive
More informationC2 COMPLETION INSTRUCTIONS
The C2 Form is completed for each screening exam at T0, T1, and T2. The C2 Form is to be completed by each of the following ACRIN-NLST study staff: the research associate (study coordinator), CT technologist,
More informationCT Low Dose Lung Cancer Screening. Part I. Journey to LDCT LCS Program
CT Low Dose Lung Cancer Screening Part I Journey to LDCT LCS Program Paul Johnson, M.S., DABHP, DABR Cleveland Clinic September 26, 2015 Lung Caner is No. 1 In Cancer Related Death In The United States
More informationLUNG CANCER SCREENING
LUNG CANCER SCREENING Christopher Lettieri MD, FACP, FCCP, FAASM Pulmonary/Critical Care Consultant to the Surgeon General Professor of Medicine Walter Reed National Military Medical Center American College
More informationEquity Issues with Lung Cancer Screening Prevent Cancer - Quantitative Imaging Workshop November 5-6, 2018 Alexandria, VA
Equity Issues with Lung Cancer Screening Prevent Cancer - Quantitative Imaging Workshop November 5-6, 2018 Alexandria, VA Mary Pasquinelli, MS, APRN, FNP-BC Pulmonary and Thoracic Medical Oncology Director,
More informationBreast Imaging Lexicon
9//201 200 BI RADS th Edition 201 BI RADS th Edition Breast Imaging Lexicon Mammographic Pathology and Assessment Categories Deborah Thames, R.T.(R)(M)(QM) The Advanced Health Education Center Nonmember:
More informationCapturing Data Elements and the Role of Imaging Informatics
Capturing Data Elements and the Role of Imaging Informatics William Hsu, PhD Medical Imaging Informatics Group Dept of Radiological Sciences University of California, Los Angeles Disclosures None Overview
More informationCT Lung Screening Implementation Challenges: ALA/ATS Implementation Microsite
CT Lung Screening Implementation Challenges: ALA/ATS Implementation Microsite Andrea McKee, MD Chair Radiation Oncology Lahey Hospital and Medical Center November 2018 2016 data, 3 years after ACS recommendation
More informationLung Cancer Screening: Current Status
Lung Cancer Screening: Current Status I have no financial relationships, arrangements or affiliations and this presentation will not include discussion of investigational or off-label use of a product
More informationLung Cancer Screening and COPD Update
Lung Cancer Screening and COPD Update Michael T. Vest, DO, FACP, FCCP Assistant Professor of Medicine Pulmonary and Critical Care Medicine Christiana Care Healthcare System Newark, DE Sidney Kimmel Medical
More informationLung Cancer Screening. Eric S. Papierniak, DO NF/SG VHA UF Health
Lung Cancer Screening Eric S. Papierniak, DO NF/SG VHA UF Health Overview Background Supporting evidence Guidelines Practical considerations Patient selection What to do with abnormal results Billing/coding
More informationSCREENING FOR EARLY LUNG CANCER. Pang Yong Kek
SCREENING FOR EARLY LUNG CANCER Pang Yong Kek Lecture Outline Why performing screening? How to improve early detection? Benefits and Risks of screening Challenges in screening Conclusion Why Performing
More informationThe solitary pulmonary nodule: Assessing the success of predicting malignancy
The solitary pulmonary nodule: Assessing the success of predicting malignancy Poster No.: C-0829 Congress: ECR 2010 Type: Scientific Exhibit Topic: Chest Authors: R. W. K. Lindsay, J. Foster, K. McManus;
More informationNational Lung Screening Trial Results
National Lung Screening Trial Results Ella A. Kazerooni, M.D. Professor & Director Cardiothoracic Radiology Associate Chair for Clinical Affairs University of Michigan NLST STOPPED! Lung cancer trial results
More informationLung Cancer Screening Benefits, Risks & Challenges
Lung Cancer Screening Benefits, Risks & Challenges Polly Sather, APRN Yale Lung Screening and Nodule Program (Yale Lung SCAN) A Multidisciplinary Comprehensive Initiative Yale Cancer Center Thoracic Oncology
More informationGoals of Presentation
Goals of Presentation Review context of lung cancer screening why is it important? Review data from NLST supporting screening with lowdose CT (LDCT) scanning Discuss the pros and cons of LDCT screening
More informationNCCN Guidelines as a Model of Extended Criteria for Lung Cancer Screening
444 Original Research NCCN Guidelines as a Model of Extended Criteria for Lung Cancer Screening Brady J. McKee, MD; Shawn Regis, PhD; Andrea K. Borondy-Kitts, MS, MPH; Jeffrey A. Hashim, MD; Robert J.
More information